Literature DB >> 25878999

Serum ferritin has correlation with HbA1c in type 2 diabetic patients.

Ali Momeni1, Mohammad Saeed Behradmanesh1, Soleiman Kheiri2, Fatemeh Abasi3.   

Abstract

BACKGROUND: Serum C-reactive protein (CRP) and ferritin are two acute phase reactants. CRP may be related to metabolic syndrome and ferritin which in turn could cause resistance to insulin and dysfunction of b cells of pancreases. The aim of the study was the evaluation of the relationship of these two acute phase reactants with some indices of diabetic control.
MATERIALS AND METHODS: In a quasi-experimental study, 67 patients with type 2 diabetes, serum CRP, ferritin, Fasting Blood Sugar (FBS), post prandial BS, Hemoglobin A1c (HbA1c), triglyceride, Low Density Lipoprotein Cholesterol (LDL) and High Density Lipoprotein cholesterol (HDL) were checked before and 3 months after the control of hyperglycemia and hyperlipidemia.
RESULTS: The mean age of the patients was 56.5 ± 9.7 (30 to 82) years. There was no significant difference between CRP before and after study; however, serum ferritin significantly decreased after study with control of hyperglycemia. FBS, 2 hours post-prandial blood sugar (2hppBS), HbA1c and triglyceride of patients decreased significantly after control of hyperglycemia and hyperlipidemia (P < 0.05); however, HDL and LDL cholesterol didn't change (P > 0.05).
CONCLUSION: Based on our results, serum ferritin decreased after decline of patients' blood sugar, so might be we used it as one of the diabetes control indices for diabetic patients.

Entities:  

Keywords:  C-reactive protein; diabetes control indices; ferritin

Year:  2015        PMID: 25878999      PMCID: PMC4386204          DOI: 10.4103/2277-9175.153900

Source DB:  PubMed          Journal:  Adv Biomed Res        ISSN: 2277-9175


INTRODUCTION

Type 2 diabetes mellitus (DM2) is an important health problem worldwide affecting about 8 percent of population.[1] The prevalence of disease continued to rise over the recent decades.[23456] The probable role of inflammatory factors and cytokines in producing DM was described by Pickup JC in 1998.[7] Similar results also were found by other studies which showed that acute phase reactants may be useful for predicting DM;[891011] however, these findings were not found in some other studies.[12] Acute phase reactants are proteins that respond to acute stress such as infection, trauma, surgery and tissue necrosis. Some of these agents are alpha-acid glycoprotein, haptoglobin, fibrinogen, C-reactive protein (CRP) and ferritin.[131415] CRP is produced by liver cells and could activate complement system and T and B lymphocytes. Erythrocyte Sediment Rate (ESR), as an acute phase reactant, is less important than CRP for evaluation of inflammation.[916] Ferritin is a complex globular protein that stores iron as soluble and non-toxic component. In oxidative stress, Fe2+ enters to cells and then changes to Fe3+, linked to ferritin and then protect cells from oxidative stress.[17] Increasing concentration of iron and ferritin in cells could cause resistance to insulin and dysfunction of β cells of pancreases. Hyperinsulinemia due to resistance to insulin may be responsible for increasing serum ferritin. It has been suggested that disturbance of iron metabolism could cause insulin resistance, hyperinsulinemia, dyslipidemia, HTN and central obesity.[1819] Since serum CRP and ferritin are two important positive acute phase reactants and increased serum level of them might be related to metabolic syndrome and insulin resistance, we have planned this study to evaluate the association between serum “CRP and ferritin” with some indices of diabetic control.

MATERIALS AND METHODS

This quasi-experimental study was performed on 67 known cases of DM2, based on ADA[20] in Emam Ali Clinic of Shahrekord, Iran. Inclusion criteria were age greater than 18 years and glomerular filtration rate (GFR) >60 mL/min based on Cockcroft-Gault formula (140-age × body weight/72 × serum creatinine). Exclusion criteria were consumption of steroid or immunosuppressive drugs and presence of infectious or autoimmune disease based on history and physical exam. Demographic information including age, gender, body weight, length, body mass indexes (BMI), duration of diabetes, blood pressure, and also laboratory findings including fasting blood sugar (FBS), 2 hours post prandial BS (2hppBS), ferritin, CRP, blood urea nitrogen (BUN), serum creatinine (Cr), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C), triglyceride, HbA1C were recorded in patients’ files. FBS, 2hppBS, serum BUN and Cr was checked by BioTechnica Instruments (BT 3000). Serum CRP as a quantitative factor was measured with immunoturbidimetric method by BT 3000. Serum ferritin was checked with electrochemiluminescence method, by ELEXIS (made by Italia). The patients were visited monthly by nephrologist or endocrinologist for control of blood glucose, lipid profile and blood pressure based on WHO guidelines. Patientsblood glucose was controlled by insulin or oral hypoglycemic agents. All laboratory tests were checked at beginning of study and 3 months later in the same laboratory. Recommendations for lifestyle modifications such as regular exercise and diet were done for all patients. This study was approved by ethical committee of Shahrekord University of Medical Science. The relationships were evaluated with Spearman's rho and t-test using SPSS software (version of 17). The results were expressed as mean ± standard deviation (SD). In order to compare variables before and after study procedure, paired t-test were used. P value less than 0.05 were considered statistically significant.

RESULTS

Forty five (67.2%) patients were women. At the beginning of the study, mean age of the patients was 56.5 ± 9.7 (30 to 82) years, mean BMI was 28.5 ± 4 (22 to 42), mean glomerular filtration rate (GFR) was 77.9 ± 12.9 (99 to 36) mL/min, and mean duration of diabetes was 6.3 ± 4.1 (1 to 15) years. Despite HDL and LDL cholesterol, which didn’t change during the study, the factors of FBS, 2hppBS, HbA1C and triglyceride decreased significantly during the study (P < 0.05). Mean serum CRP, before and after the study were 1.43 ± 0.09 mg/L and 1.42 ± 0.08 mg/L, respectively (normal range: 1 to 3 mg/L). There was a significant negative correlation between serum ferritin and duration of diabetes (r = 0.259; P = 0.034). There was a weak positive correlation between CRP and HbA1c at beginning of study (r = 0.251; P = 0.042) [Table 1]. In one patient, serum CRP was 115 and 111, respectively, before and after study; therefore, this patient was excluded from analysis.
Table 1

Summary of variables of the patients during the study

Summary of variables of the patients during the study Mean serum ferritin, before and after the control of hyperglycemia were 115 ± 109.4 ng/mL and 91.4 ± 61.9 ng/mL, respectively (normal range: Males: 23 to 336 ng/mL and Females: 11 to 306 ng/mL). There was no significant difference between CRP before and after the study; however, serum ferritin significantly decreased after 3 months follow-up, which means that serum ferritin would decrease with reducing serum FBS and post-prandial BS [Figures 1 and 2].
Figure 1

Scatter plot of ferritin based on diabetic duration at the beginning of study

Figure 2

Scatter plot of Serum CRP based on HbA1C at the beginning of study

Scatter plot of ferritin based on diabetic duration at the beginning of study Scatter plot of Serum CRP based on HbA1C at the beginning of study

DISCUSSION

This study was conducted to evaluate the relationship between two acute phase reactants (CRP and ferritin) with diabetic control indices (FBS, 2hppBS, HbA1c). Our study showed that in diabetic patients, despite the improvement of diabetic control indices, the amount of serum CRP was not changed; however, serum ferritin level had a relationship with hyperglycemia and its level decreased with lowering of serum blood glucose. There are different and sometimes controversial results in the other studies. In Ebrahimi's study, in 80 cases and 73 controls among participant of Tehran glucose lipid cohort study, whom followed for 3.6 years, serum CRP was correlated with systolic and diastolic blood pressure, total cholesterol and triglyceride and FBS, but not with HDL cholesterol and 2hppBS. The authors concluded that CRP may have a role in production of diabetes and can use as a predictor of DM in the future.[21] In another study, Festa evaluated 1407 cases who were at high risk of developing DM for 5 years and observed that DM was developed in 144 cases, who had greater serum level of CRP, fibrinogen and plasminogen activator inhibitor-1 compared to another patients.[9] In 9486 adult population, Ford checked serum insulin, hemoglobin A1C (HbA1c), fasting blood sugar (FBS), ferritin, and found a significant correlation between serum ferritin with HbA1c, FBS and serum insulin. He concluded that elevated serum ferritin is a risk factor of DM.[22] Similar results were obtained in our study, so after improvement of diabetes indexes, ferritin was decreased. Wrede in a study on 2000 German population showed that serum ferritin is higher in patients with BMI >25 kg/m2, cholesterol >200 mg/dl, systolic blood pressure >160 mmHg and in women with diabetes. He found a positive correlation between serum ferritin and presence of insulin resistance syndrome in a representative population.[23] In Ashoorapour's study, there was a correlation between serum ferritin and FBS, HbA1C, serum insulin.[19] Thorand B in MONICA study showed that men with high levels of CRP had a 2.7 times higher risk of developing diabetes compared with men in the lower CRP. He concluded that low-grade systemic inflammation is correlated with an increased risk of type 2 diabetes mellitus in middle-aged men; however, after adjustment for BMI, smoking and systolic blood pressure (SBP), the observed association was substantially reduced and became not significant.[8] Our study had some limitations such as difficulty of regular follow-up of the patients during the study, relative small sample size, necessity of performance of exams only in a single laboratory and non-cooperation of some patients, which may cause them to be excluded from study.

CONCLUSION

Based on our results, serum ferritin decreased after decline of patientsblood sugar which might be used it as one of the diabetes control indices for diabetic patients.
  21 in total

Review 1.  Phylogenetic perspectives in innate immunity.

Authors:  J A Hoffmann; F C Kafatos; C A Janeway; R A Ezekowitz
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

2.  Prevalence of diabetes among men and women in China.

Authors:  Wenying Yang; Juming Lu; Jianping Weng; Weiping Jia; Linong Ji; Jianzhong Xiao; Zhongyan Shan; Jie Liu; Haoming Tian; Qiuhe Ji; Dalong Zhu; Jiapu Ge; Lixiang Lin; Li Chen; Xiaohui Guo; Zhigang Zhao; Qiang Li; Zhiguang Zhou; Guangliang Shan; Jiang He
Journal:  N Engl J Med       Date:  2010-03-25       Impact factor: 91.245

3.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 4.  Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms.

Authors:  E C Theil
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

Review 5.  The phenomenon of the acute phase response.

Authors:  I Kushner
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

6.  The relation of body fat mass and distribution to markers of chronic inflammation.

Authors:  A Festa; R D'Agostino; K Williams; A J Karter; E J Mayer-Davis; R P Tracy; S M Haffner
Journal:  Int J Obes Relat Metab Disord       Date:  2001-10

Review 7.  US public health and the 21st century: diabetes mellitus.

Authors:  J McKinlay; L Marceau
Journal:  Lancet       Date:  2000-08-26       Impact factor: 79.321

8.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

Authors:  Sarah Wild; Gojka Roglic; Anders Green; Richard Sicree; Hilary King
Journal:  Diabetes Care       Date:  2004-05       Impact factor: 19.112

9.  Inflammatory markers and risk of developing type 2 diabetes in women.

Authors:  Frank B Hu; James B Meigs; Tricia Y Li; Nader Rifai; JoAnn E Manson
Journal:  Diabetes       Date:  2004-03       Impact factor: 9.461

10.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2010-01       Impact factor: 19.112

View more
  5 in total

1.  Role of Regulatory Proteins Involved in Iron Homeostasis in Pulmonary Tuberculosis Patients and Their Household Contacts.

Authors:  Sudhasini Panda; Shah Faisal; Krishna Kumar; Diravya M Seelan; Alpana Sharma; Neeraj Kumar Gupta; Sudip Datta; Archana Singh
Journal:  Indian J Clin Biochem       Date:  2021-01-06

2.  Serum Ferritin in Metabolic Syndrome-Mechanisms and Clinical Applications.

Authors:  Shrey Kumar Srivastav; Irfan Ahmad Mir; Naman Bansal; Pankaj Kumar Singh; Rashmi Kumari; Ajoy Deshmukh
Journal:  Pathophysiology       Date:  2022-06-17

3.  Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis.

Authors:  Dana L Sharma; Hari Vishal Lakhani; Rebecca L Klug; Brian Snoad; Rawan El-Hamdani; Joseph I Shapiro; Komal Sodhi
Journal:  J Clin Cell Immunol       Date:  2017-09-29

4.  Salivary Ferritin Changes in Patients with COVID-19.

Authors:  Lorena Franco-Martínez; José J Cerón; María R Vicente-Romero; Enrique Bernal; Alberto Torres Cantero; Fernando Tecles; Cristina Sánchez Resalt; Mónica Martínez; Asta Tvarijonaviciute; Silvia Martínez-Subiela
Journal:  Int J Environ Res Public Health       Date:  2021-12-21       Impact factor: 3.390

5.  Ferritin levels and COVID-19.

Authors:  Manuel Vargas-Vargas; Christian Cortés-Rojo
Journal:  Rev Panam Salud Publica       Date:  2020-06-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.